The experience of the first Russian latanoprost 0.005% (Trilactan) use in the treatment of primary open-angle glaucoma

Abstract

Summary. The problem of the reproduced (generic) and original (branded) medications coexistence on the pharmaceutical market is very relevant for Russia. Numerous polls have shown that very few among patients and even doctors clearly understand the differences between original drugs and generics, nor they know how these drugs are produced, and what advantages and weaknesses they have.
 Aim. This paper covers the study of Trilactan (0.005% latanoprost, Solopharm, Russia) use in patients with different stages of primary open-angle glaucoma, and includes the analysis of the hypotensive effect and adverse events rate.
 Material and methods. The study included 47 patients divided into 3 groups. The first group included 17 treatment-nave patients (32 eyes). The second group included 14 patients (28 eyes) previously treated with latanoprost 0.005% once a day in the evening at least for a month. The third group consisted of 16 patients (32 eyes) treated with beta-blockers or carbonic anhydrase inhibitors, in whom the target level of intraocular pressure had not been reached. All patients received 1 drop of Trilactan every evening; the observation lasted for 3 months.
 Conclusions. The treatment was well tolerated. The intraocular pressure decrease was observed in all cases (p 0.05). Local and systemic adverse events under Trilactan treatment did not differ from possible side effects typical to the drugs of this pharmacological group in terms of its type and rate.